Compstatin: a complement inhibitor on its way to clinical application
about
Complement in age-related macular degeneration: a focus on functionComplement inhibitors to treat IgM-mediated autoimmune hemolysisInhibiting Alternative Pathway Complement Activation by Targeting the Factor D ExositeComplement System Part II: Role in ImmunityDesign of a modified mouse protein with ligand binding properties of its human analog by molecular dynamics simulations: the case of C3 inhibition by compstatinA humanized antibody that regulates the alternative pathway convertase: potential for therapy of renal disease associated with nephritic factorsComplement activation on platelets correlates with a decrease in circulating immature platelets in patients with immune thrombocytopenic purpuraMolecules Great and Small: The Complement System.Can cells and biomaterials in therapeutic medicine be shielded from innate immune recognition?Review: Complement and its regulatory proteins in kidney diseases.CR1/2 is an important suppressor of Adenovirus-induced innate immune responses and is required for induction of neutralizing antibodiesInhibitors of C5 complement enhance vaccinia virus oncolysis.Protection of nonself surfaces from complement attack by factor H-binding peptides: implications for therapeutic medicine.Mediation of a non-proteolytic activation of complement component C3 by phospholipid vesicles.Conjugation to albumin-binding molecule tags as a strategy to improve both efficacy and pharmacokinetic properties of the complement inhibitor compstatinComplement-mediated inhibition of neovascularization reveals a point of convergence between innate immunity and angiogenesis.Novel analogues of the therapeutic complement inhibitor compstatin with significantly improved affinity and potency.Complement System Part I - Molecular Mechanisms of Activation and Regulation.Complementing the inflammasome.New insights of an old defense system: structure, function, and clinical relevance of the complement system.A new generation of potent complement inhibitors of the Compstatin family.Synthesis and activity of thioether-containing analogues of the complement inhibitor compstatin.Therapeutic C3 inhibitor Cp40 abrogates complement activation induced by modern hemodialysis filtersInnate immunity activation on biomaterial surfaces: a mechanistic model and coping strategies.Rare loss-of-function mutation in complement component C3 provides insight into molecular and pathophysiological determinants of complement activityCompstatin: a C3-targeted complement inhibitor reaching its prime for bedside intervention.Identification of peptidic inhibitors of the alternative complement pathway based on Staphylococcus aureus SCIN proteins.Molecular dynamics in drug design: new generations of compstatin analogs.Interactions between coagulation and complement--their role in inflammationAnaphylatoxin C5a creates a favorable microenvironment for lung cancer progression.Mesenchymal stem cells are injured by complement after their contact with serumTherapeutic control of complement activation at the level of the central component C3.Anti-complement component 5 antibody targeting MG4 domain inhibits choroidal neovascularization.Paroxysmal nocturnal hemoglobinuria: a complement-mediated hemolytic anemiaNew analogs of the clinical complement inhibitor compstatin with subnanomolar affinity and enhanced pharmacokinetic propertiesComplement therapeutics in inflammatory diseases: promising drug candidates for C3-targeted intervention.Manipulating the mediator: modulation of the alternative complement pathway C3 convertase in health, disease and therapy.Progress and Trends in Complement TherapeuticsThe relative merits of therapies being developed to tackle inappropriate ('self'-directed) complement activationComplement inhibition prevents oncolytic vaccinia virus neutralization in immune humans and cynomolgus macaques
P2860
Q24635874-24ADB788-45F9-4999-95FD-AAF89D783AF2Q26777628-53517027-7326-4C67-B062-9C98C2DADFC8Q27677455-6B906F6B-A789-4C89-9A93-C99BDB39DE96Q28263460-26CDBEE4-D956-4605-B85D-3B382CA7014FQ30408033-B0CA6D1C-0A10-46CC-B7C0-A0FB208AF2D5Q30409539-E5C04DD0-4D3B-4009-97C2-510747D28E6BQ33387105-2E5AFD7E-82D1-4116-9DAB-F29C00F986E8Q33419651-1EA9A179-B23B-42E6-970A-3D7AD4207207Q33636425-018AAB11-60A8-4B6B-9EA9-5507DB9DF22BQ33647738-29A6F4D6-FD4D-46A3-934F-2C7137165907Q33687979-62BB40EF-B077-40F8-9C34-91590A07D836Q33768177-E9A45723-A508-4830-AF68-24C5D9B00B4FQ33825957-602B5E46-ED55-4747-B216-8A6967899EEAQ33925578-829A461C-CDD4-4201-999C-16CE4B3CF1ECQ34254555-27FBE261-B2E3-41D4-A469-ECBCB604132AQ34374022-AB340106-563E-4A0B-84DF-3EB35183B61EQ34459360-7BCC330F-C089-4C75-9FF5-0F7F2986E85AQ34481071-4B21F267-1FCD-4BA3-88F4-15E07C394DCCQ34501875-ED4F7D6C-390A-4E1E-A415-A4E258CC2506Q34699496-51FC9F6F-2543-4851-BA33-B09834B6EF4BQ34984736-94A1C45A-405E-4791-9F12-3BE92CEEC304Q35109329-8F694E42-2600-48DB-88C0-D77937343A61Q35164180-E04E95C6-4EA9-4742-9E42-9BBCCEB4F155Q35194713-13F496D3-D2C7-4FD6-BE79-E09A7FFA9015Q35205450-0D739DCC-9595-4A3E-94CD-920F80E893DFQ35236103-5FBC83C4-A88E-4599-82CD-42F4DAAC572EQ35655909-1F6A0699-EABA-4AD6-9F12-42B1B4830FA7Q35871691-834E5DE4-DFE1-41FC-AEEB-F58F5FEFE840Q36022738-1B599BE9-7D78-4DDD-8664-9182AF3A5FB4Q36338990-F68616D9-D883-4C2B-BB95-A57972B93D6BQ36352514-D03274A5-31E7-4451-9AA4-D93BDFB49E31Q36363005-E610DDA6-E83D-4444-8499-69FE3D0CE700Q36364687-4F4017B3-7423-48D6-91D3-4F59680EF0C5Q36416292-36A2ABCA-0E2C-45ED-B67F-2BE2BAB4D3C7Q36456593-1BC0079C-4C12-4791-829F-0D864C38F95DQ36460034-BFAFBBC2-77F3-45DE-8C40-70F5F2D9D94EQ36463266-BD16F352-F5C8-4B5F-8436-C94DFDB2C365Q36479278-37633C6E-7A20-4EF9-A6DD-3E58F85F4663Q36643354-8AF3036C-D6C4-490A-B331-708048EDEEC2Q36756690-D78DCD94-9C86-489F-841D-EEC98F162102
P2860
Compstatin: a complement inhibitor on its way to clinical application
description
2008 nî lūn-bûn
@nan
2008 թուականին հրատարակուած գիտական յօդուած
@hyw
2008 թվականին հրատարակված գիտական հոդված
@hy
2008年の論文
@ja
2008年学术文章
@wuu
2008年学术文章
@zh-cn
2008年学术文章
@zh-hans
2008年学术文章
@zh-my
2008年学术文章
@zh-sg
2008年學術文章
@yue
name
Compstatin: a complement inhibitor on its way to clinical application
@ast
Compstatin: a complement inhibitor on its way to clinical application
@en
Compstatin: a complement inhibitor on its way to clinical application
@nl
type
label
Compstatin: a complement inhibitor on its way to clinical application
@ast
Compstatin: a complement inhibitor on its way to clinical application
@en
Compstatin: a complement inhibitor on its way to clinical application
@nl
prefLabel
Compstatin: a complement inhibitor on its way to clinical application
@ast
Compstatin: a complement inhibitor on its way to clinical application
@en
Compstatin: a complement inhibitor on its way to clinical application
@nl
P2860
P1476
Compstatin: a complement inhibitor on its way to clinical application
@en
P2093
Daniel Ricklin
John D Lambris
P2860
P304
P356
10.1007/978-0-387-78952-1_20
P407
P577
2008-01-01T00:00:00Z